Log in

NASDAQ:SAGE - SAGE Therapeutics Stock Price, Forecast & News

$29.50
-2.00 (-6.35 %)
(As of 03/31/2020 06:00 AM ET)
Today's Range
$29.04
Now: $29.50
$31.61
50-Day Range
$26.15
MA: $49.21
$70.38
52-Week Range
$25.01
Now: $29.50
$193.56
Volume874,899 shs
Average Volume1.02 million shs
Market Capitalization$1.53 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.59
Sage Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system (CNS) disorders. Its lead product candidate is ZULRESSO, a proprietary intravenous formulation of brexanolone that has completed Phase III clinical trials for the treatment of postpartum depression (PPD). The company's product pipeline also includes SAGE-217, a novel neuroactive steroid, which is in Phase III clinical trials for treating PPD, major depressive disorders, bipolar depression, and sleep disorders; and SAGE-324, a novel neuroactive steroid that has completed Phase I clinical trials to treat various neurological conditions, including essential tremor and epileptiform disorders. In addition, its product pipeline comprises SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which has completed Phase I clinical trial for the treatment of depression, Huntington's disease, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain; and SAGE-689, a novel GABAA receptor positive allosteric modulator that is in preclinical stage to treat acute and chronic CNS disorders. Sage Therapeutics, Inc. has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of SAGE-217 in Japan, Taiwan, and South Korea. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Read More
SAGE Therapeutics logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:SAGE
CUSIPN/A
Phone617-299-8380

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$6.87 million
Book Value$18.23 per share

Profitability

Net Income$-680,240,000.00
Net Margins-9,904.45%

Miscellaneous

Employees637
Market Cap$1.53 billion
Next Earnings Date5/7/2020 (Estimated)
OptionableOptionable

Receive SAGE News and Ratings via Email

Sign-up to receive the latest news and ratings for SAGE and its competitors with MarketBeat's FREE daily newsletter.


SAGE Therapeutics (NASDAQ:SAGE) Frequently Asked Questions

How has SAGE Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

SAGE Therapeutics' stock was trading at $42.30 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, SAGE stock has decreased by 30.3% and is now trading at $29.50. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of SAGE Therapeutics?

20 Wall Street analysts have issued "buy," "hold," and "sell" ratings for SAGE Therapeutics in the last year. There are currently 6 hold ratings and 14 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for SAGE Therapeutics.

When is SAGE Therapeutics' next earnings date?

SAGE Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, May 7th 2020. View our earnings forecast for SAGE Therapeutics.

How were SAGE Therapeutics' earnings last quarter?

SAGE Therapeutics Inc (NASDAQ:SAGE) released its quarterly earnings data on Thursday, February, 27th. The biopharmaceutical company reported ($3.25) EPS for the quarter, topping analysts' consensus estimates of ($3.62) by $0.37. The biopharmaceutical company earned $1.96 million during the quarter, compared to analysts' expectations of $3.76 million. SAGE Therapeutics had a negative return on equity of 59.83% and a negative net margin of 9,904.45%. The company's quarterly revenue was up 617.9% on a year-over-year basis. During the same period in the previous year, the business earned ($3.38) EPS. View SAGE Therapeutics' earnings history.

What price target have analysts set for SAGE?

20 equities research analysts have issued 12 month target prices for SAGE Therapeutics' shares. Their forecasts range from $28.00 to $263.00. On average, they expect SAGE Therapeutics' share price to reach $100.05 in the next year. This suggests a possible upside of 239.2% from the stock's current price. View analysts' price targets for SAGE Therapeutics.

Has SAGE Therapeutics been receiving favorable news coverage?

News coverage about SAGE stock has trended somewhat positive this week, according to InfoTrie. The research group rates the sentiment of press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. SAGE Therapeutics earned a news impact score of 1.5 on InfoTrie's scale. They also assigned news articles about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the stock's share price in the next few days. View the latest news aboutSAGE Therapeutics.

Who are some of SAGE Therapeutics' key competitors?

What other stocks do shareholders of SAGE Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other SAGE Therapeutics investors own include NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), AbbVie (ABBV), Intercept Pharmaceuticals (ICPT), Advanced Micro Devices (AMD), Netflix (NFLX), Gilead Sciences (GILD), salesforce.com (CRM) and Twitter (TWTR).

Who are SAGE Therapeutics' key executives?

SAGE Therapeutics' management team includes the following people:
  • Dr. Jeffrey M. Jonas, CEO, Pres & Director (Age 66)
  • Ms. Kimi E. Iguchi, CFO & Treasurer (Age 57)
  • Dr. Albert J. Robichaud, Chief Scientific Officer (Age 58)
  • Ms. Anne Marie Cook, Sr. VP, Gen. Counsel & Sec. (Age 57)
  • Mr. Michael Cloonan, Chief Bus. Officer (Age 48)

What is SAGE Therapeutics' stock symbol?

SAGE Therapeutics trades on the NASDAQ under the ticker symbol "SAGE."

How do I buy shares of SAGE Therapeutics?

Shares of SAGE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is SAGE Therapeutics' stock price today?

One share of SAGE stock can currently be purchased for approximately $29.50.

How big of a company is SAGE Therapeutics?

SAGE Therapeutics has a market capitalization of $1.53 billion and generates $6.87 million in revenue each year. The biopharmaceutical company earns $-680,240,000.00 in net income (profit) each year or ($13.38) on an earnings per share basis. SAGE Therapeutics employs 637 workers across the globe. View additional information about SAGE Therapeutics.

What is SAGE Therapeutics' official website?

The official website for SAGE Therapeutics is http://www.sagerx.com/.

How can I contact SAGE Therapeutics?

SAGE Therapeutics' mailing address is 215 FIRST STREET, CAMBRIDGE MA, 02142. The biopharmaceutical company can be reached via phone at 617-299-8380 or via email at [email protected]


MarketBeat Community Rating for SAGE Therapeutics (NASDAQ SAGE)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  562 (Vote Outperform)
Underperform Votes:  337 (Vote Underperform)
Total Votes:  899
MarketBeat's community ratings are surveys of what our community members think about SAGE Therapeutics and other stocks. Vote "Outperform" if you believe SAGE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SAGE will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/31/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel